I know they've streamlined their clinical trial and approval processes. I believe so that a product can be marketed after (during?) phase II.
And every stem cell/regenerative medicine biotech is hyping Japan as the nirvana of capital, innovation and springboard to "$ multi-billion breakthrough".
That said, some companies have obtained significant $$$ there, and are certainly trying to take advantage of the streamlined approval processes to get their products to market.
Will be interesting to see how much of the hype bears fruit.
- Forums
- ASX - By Stock
- MSB
- Japanese like stem cell technologies
Japanese like stem cell technologies, page-6
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.141B |
Open | High | Low | Value | Volume |
$1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43508 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 34138 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 43508 | 1.000 |
1 | 15862 | 0.995 |
5 | 58523 | 0.990 |
3 | 49529 | 0.985 |
3 | 53984 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.005 | 34138 | 2 |
1.010 | 59763 | 4 |
1.015 | 35684 | 2 |
1.020 | 77095 | 6 |
1.025 | 66956 | 6 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online